B+
Bull case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
AGMB
AgomAb TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The STENOVA extension offers encouraging longer-term safety and disease-control signals, while the Phase 1 IPF cohort supports advancing a second program. June 30 cash and investments of €252 million were expected by management to fund operations into the first half of 2029.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -1.6.
What can break
AGMB-447 IPF evidence comes from 10 patients over 14 days; cough and bronchospasm were reported, and higher-dose adverse events were more frequent. [#PR-EARNINGS-2026-09-14] Company release
Momentum
4
Value
46
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.00 · Bull $14.00 · Bear $5.50Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $37.79
Why
Momentum4 · Δ7d +1.6
Value46 · Δ7d +0.0
Sentiment63 · Δ7d -1.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -1.6.
Contradictions & invalidation
- • AGMB-447 IPF evidence comes from 10 patients over 14 days; cough and bronchospasm were reported, and higher-dose adverse events were more frequent. [#PR-EARNINGS-2026-09-14] Company release
- • Only 37 of 49 extension entrants completed 48 weeks, and optional Week 48 endoscopy data were too limited for reliable interpretation. [#PR-2026-10-01] Company release
- • The extension was open-label and its optional endoscopy data were inadequate for reliable interpretation.
Catalyst clock
2026-10-01
STENOVA extension readout and sharp price reversal
Lead driver: Sentiment · See AI snapshot
Momentum
4
8% active weight
Current posture
7d trendFlat
Δ7d
+1.6
Δ21d
-0.8
Value
46
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
0.0
Sentiment
63
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.6
Δ21d
-0.7
Why this grade
Composite grade D. Momentum 3.9 / Value 46.5 / Sentiment 62.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$422.06M
Beta
-
Shares Out
49.25M
P/E (TTM) · Derived
-5.9
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-
EPS YoY
+61.8%
Gross Margin
-
Op Margin
-
Net Debt
-$135.37M
Current Ratio
12.88
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data